SCHEMBL292808

SCHEMBL292808

C=CCOc1ccccc1CC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIG1 P18858 1/20 0.53
CXCL8 P10145 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TSHR P16473 2/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
AKR1B1 P15121 1/20 0.47
CFD P00746 1/20 0.47
PLG P00747 1/20 0.47
PLAU P00749 1/20 0.47
F11 P03951 1/20 0.47
KLKB1 P03952 1/20 0.47
F7 P08709 1/20 0.47
TPSB2 P20231 1/20 0.47
CHRM1 P11229 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31414031 1.00 LIG1 (0.53) LIG1CXCL8L3MBTL1MEN1KMT2A
SCHEMBL25380983 0.87 LIG1 (0.53) LIG1L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL17008015 0.84 KDM4E (0.57) CXCL8L3MBTL1KMT2AALDH1A1KDM4E
SCHEMBL28485379 0.84 THRA (0.51) LIG1MEN1KMT2AALDH1A1KDM4E
SCHEMBL6686753 0.81 MAPT (0.47) LIG1CXCL8L3MBTL1MEN1KMT2A
SCHEMBL28640918 0.80 ALDH1A1 (0.51) LIG1L3MBTL1ALDH1A1KDM4ETSHR
SCHEMBL21455647 0.80 L3MBTL1 (0.55) CXCL8L3MBTL1ALDH1A1KDM4EHPGD
SCHEMBL8754795 0.80 ALDH1A1 (0.58) LIG1L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL12986104 0.79 CXCL8 (0.54) CXCL8L3MBTL1KDM4EAKR1B1CFD
SCHEMBL22323844 0.79 L3MBTL1 (0.61) LIG1L3MBTL1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
EP-4604951-A1 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF AMIRA THERAPEUTICS, S.L. (ES) 2025-08-27 EP disclosed
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 EP disclosed
US-12384800-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2025-08-12 US disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 US disclosed
WO-2025050647-A1 IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 晟迪生物医药(苏州)有限公司 2025-03-13 WO disclosed
US-12215100-B2 Anticancer compounds PHARMA MAR, S.A. (ES) 2025-02-04 US disclosed
EP-4419513-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2024-08-28 EP disclosed
US-12006311-B2 Compounds for use in preventing or treating cancer FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) 2024-06-11 US disclosed
CN-114751920-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
WO-2009077401-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-06-25 WO disclosed
US-20090143432-A1 Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
WO-2009035652-A1 SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3] DIOXOLES AND DERIVATIVES THEREOF CONCERT PHARMACEUTICALS, INC. (US) 2009-03-19 WO disclosed
EP-2032551-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-03-11 EP disclosed
WO-2009017671-A1 SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. (US) 2009-02-05 WO disclosed
WO-2007144423-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2007-12-21 WO disclosed
EP-1307468-A1 MACROLIDE ANTIBIOTICS Pfizer Products Inc. (US) 2003-05-07 EP disclosed
WO-2002012260-A1 MACROLIDE ANTIBIOTICS PFIZER PRODUCTS INC. (US) 2002-02-14 WO disclosed
EP-0256586-A1 Process for the preparation of esters of 4-(2,3-epoxypropoxy)phenylacetic acid and 4-(2-hydroxy-3-isopropylamino-propoxy)phenylacetic acid and/or atenolol in stereospecific form GIST-BROCADES N.V. (NL) 1988-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384800-B2 Antitumoral compounds TP53, TOP1, MCL1 LIG1 1299/4885CXCL8 1680/4885L3MBTL1 4215/4885
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB LIG1 1533/4885CXCL8 2094/4885L3MBTL1 1938/4885
US-20090143432-A1 Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof COMT, DRD2, DRD3 LIG1 1236/4885CXCL8 4757/4885L3MBTL1 3072/4885
US-12006311-B2 Compounds for use in preventing or treating cancer UGT1A3, UGT1A1, UGT1A6 LIG1 3662/4885CXCL8 2337/4885L3MBTL1 2919/4885
US-12215100-B2 Anticancer compounds TP53, MCL1, MYC LIG1 2542/4885CXCL8 3856/4885L3MBTL1 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.